YiChang HEC ChangJiang Pharmaceutical Co Ltd 2019 SR
The report highlights YiChang HEC ChangJiang Pharmaceutical's 2019 ESG performance, focusing on its mission 'For Everyone's Health.' Key achievements include the successful consistency evaluation of its core anti-influenza drug, Oseltamivir phosphate, and significant progress in its R&D pipeline for endocrine and metabolic diseases. The company reported a 147.92% revenue increase and emphasized its commitment to environmental protection, investing over RMB 5.29 million in green initiatives. Socially, it maintained a 100% safety training coverage and actively contributed to COVID-19 relief efforts in early 2020.
Company: YiChang HEC ChangJiang Pharmaceutical Co Ltd
Sector: Health Care
Country: China
Year: 2019
Type: SR
Pages: 86
YiChang HEC ChangJiang Pharmaceutical Co Ltd
ESG Report
The report highlights YiChang HEC ChangJiang Pharmaceutical's 2019 ESG performance, focusing on its mission 'For Everyone's Health.' Key achievements include the successful consistency evaluation of its core anti-influenza drug, Oseltamivir phosphate, and significant progress in its R&D pipeline for endocrine and metabolic diseases. The company reported a 147.92% revenue increase and emphasized its commitment to environmental protection, investing over RMB 5.29 million in green initiatives. Socially, it maintained a 100% safety training coverage and actively contributed to COVID-19 relief efforts in early 2020.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Employees